Jack Hedberg
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
24
Citations
90
Est. group size
~5
Recurring co-author estimate
Active years
12
Publishing since 2015
Jack Hedberg's research centers on using engineered oncolytic viruses (viruses modified to selectively infect and kill tumor cells) to treat brain tumors like glioma and medulloblastoma, with a focus on how these viruses reshape the immune system within tumors. Recent work combines virus engineering (e.g., adding immune-signaling genes like IL-12 and IL-27) with single-cell and multiomic profiling to understand immune cell responses and identify new therapeutic targets. Earlier work also examined genetic causes of immune dysfunction linked to telomere maintenance.
Publication output was low and sporadic from 2017–2023 (about one paper per year) but increased sharply in 2024–2025, suggesting a recent period of growing research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Multiomic Characterization of Meningiomas Informs Cell of Origin and Identifies Immune Dysregulation at the Blood-CSF Barrier
Research Square · 2026
- Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models
Journal for ImmunoTherapy of Cancer · 2025
- Oncolytic Virus Therapies in Malignant Gliomas: Advances and Clinical Trials
Cancers · 2025
- Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response
Viruses · 2025
- 1054 Multiomic Characterization of Meningiomas Informs Celltype of Origin and Identifies Immune Dysregulation at the Blood-CSF Barrier
Neurosurgery · 2025
- Abstract 955: Single cell sequencing delineates immune features of oncolytic virus therapeutic response in murine high-grade gliomas
Cancer Research · 2025
- Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- 894 oHSV-IL27 expression improves survival and induces protective immune memory in a CD4 T cell dependent mechanism in a preclinical murine glioma model
Regular and Young Investigator Award Abstracts · 2025
- Improved detection of DNA replication fork-associated proteins
Cell Reports · 2024
- Ruxolitinib and oHSV combination therapy increases CD4 T cell activity and germinal center B cell populations in murine sarcoma
Molecular Therapy Oncology · 2024
- Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy
Frontiers in Immunology · 2024
- Primary murine high-grade glioma cells derived from RCAS/tv-a diffuse glioma model reprogram naive T cells into immunosuppressive regulatory T lymphocytes
Molecular Therapy Oncology · 2024
- Abstract B030: IL-27 expressing oncolytic HSV prolongs survival in a syngeneic murine malignant glioma model in a CD8 T cell-dependent manner
Cancer Immunology Research · 2024
- Abstract 6654: Oncolytic virotherapy targeting high-grade glioma tumor antigens
Cancer Research · 2024
- 999 Oncolytic virotherapy-mediated intratumoral IL-12 and its impact on immune cell function: insights from spectral flow cytometry
Regular and Young Investigator Award Abstracts · 2024
- Regular and Young Investigator Award Abstracts×4
- Cancer Research×3
- Molecular Therapy Oncology×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Nature Communications×1
- Chelsea Bolyard
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kevin A. Cassady
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Nicholas Denton
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Roland W. Herzog
Biochemistry, Genetics and Molecular Biology · Indiana University
- Timothy P. Cripe
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile